Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis

Proteomics

Volumn 15, Issue 19, 2015, Pages 3361-3369

  Kroksveen, Ann C ^a   Jaffe, Jacob D ^b   Aasebø, Elise ^a   Barsnes, Harald ^a   Bjørlykke, Yngvild ^a   Franciotta, Diego ^c   Keshishian, Hasmik ^b   Myhr, Kjell Morten ^a,d   Opsahl, Jill A ^a   van Pesch, Vincent ^e   Teunissen, Charlotte E ^f   Torkildsen, Øivind ^a,d   Ulvik, Rune J ^a,d   Vethe, Heidrun ^a   Carr, Steven A ^b   Berven, Frode S ^a,d  

^a UNIVERSITY OF BERGEN   (Norway)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarkers; Biomedicine; Cerebrospinal fluid; Multiple sclerosis; Quantitative mass spectrometry; Secretogranin 1

Indexed keywords

BIOLOGICAL MARKER; CEREBELLIN 1; CHITINASE 3 LIKE PROTEIN 1; CHROMOGRANIN B; GLUTAMATE RECEPTOR; MUCIN; NEUROSERPIN; PROTEIN DERIVATIVE; TESTICAN 2; UNCLASSIFIED DRUG; CHGB PROTEIN, HUMAN;

ARTICLE; CATION EXCHANGE; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; MALE; MASS SPECTROMETRY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; QUANTITATIVE ANALYSIS; ADULT; CEREBROSPINAL FLUID; DOWN REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; BIOMARKERS; CHROMOGRANIN B; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MULTIPLE SCLEROSIS; PROTEOMICS;

EID: 84942985688     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201400142     Document Type: Article

References (36)

1. Morrissey, S. P., Miller, D. H., Kendall, B. E., Kingsley, D. P. et al., The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 1993, 116 (Pt 1), 135-146.
2. Paolino, E., Fainardi, E., Ruppi, P., Tola, M. R. et al., A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 1996, 60, 572-575.
3. McDonald, W. I., Compston, A., Edan, G., Goodkin, D. et al., Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. 2001, 50, 121-127.
4. Polman, C. H., Reingold, S. C., Edan, G., Filippi, M. et al., Diagnostic criteria for multiple sclerosis: 2005 Revisions to the "McDonald Criteria". Ann. Neurol. 2005, 58, 840-846.
5. Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R. et al., Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338, 278-285.
6. Jacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P. et al., Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N. Engl. J. Med. 2000, 343, 898-904.
7. Comi, G., Filippi, M., Barkhof, F., Durelli, L. et al., Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001, 357, 1576-1582.
8. Stuve, O., Bennett, J. L., Hemmer, B., Wiendl, H. et al., Pharmacological treatment of early multiple sclerosis. Drugs 2008, 68, 73-83.
9. Kroksveen, A., Opsahl, J., Aye, T., Ulvik, R., Berven, F., Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. J. Proteomics 2011, 74, 371-388.
10. Kroksveen, A. C., Opsahl, J. A., Guldbrandsen, A., Myhr, K. M. et al., Cerebrospinal fluid proteomics in multiple sclerosis. Biochim. Biophys. Acta 2014, 1854, 746-756.
11. Teunissen, C. E., Petzold, A., Bennett, J. L., Berven, F. S. et al., A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009, 73, 1914-1922.
12. Kroksveen, A. C., Aasebo, E., Vethe, H., VanPesch, V. et al., Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM. J. Proteomics 2013, 78, 312-325.
13. Comabella, M., Fernandez, M., Martin, R., Rivera-Vallve, S. et al., Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010, 133, 1082-1093.
14. Mattsson, N., Ruetschi, U., Podust, V. N., Stridsberg, M. et al., Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis. J. Neurochem. 2007, 103, 1932-1939.
15. Aasebo, E., Opsahl, J. A., Bjorlykke, Y., Myhr, K. M. et al., Effects of blood contamination and the rostro-caudal gradient on the human cerebrospinal fluid proteome. PLoS One 2014, 9, e90429.
16. Rappsilber, J., Ishihama, Y., Mann, M., Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal Chem 2003, 75, 663-670.
17. Aebersold, R., Burlingame, A. L., Bradshaw, R. A., Western blots versus selected reaction monitoring assays: time to turn the tables? Mol. Cell. Proteomics 2013, 12, 2381-2382.
18. Stoop, M. P., Dekker, L. J., Titulaer, M. K., Burgers, P. C. et al., Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry. Proteomics 2008, 8, 1576-1585.
19. Teunissen, C., Menge, T., Altintas, A., Álvarez-Cermeño, J. et al., Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult. Scler. 2013, 19, 1802-1809.
20. Teunissen, C., Tumani, H., Bennett, J., Berven, F. et al., Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. Multiple sclerosis international 2011, 2011, 246412.
21. Karussis, D., The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J. Autoimmun. 2014, 48, 134-142.
22. Karp, N. A., Huber, W., Sadowski, P. G., Charles, P. D. et al., Addressing accuracy and precision issues in iTRAQ quantitation. Mol Cell Proteomics 2010, 9, 1885-1897.
23. Savitski, M. M., Mathieson, T., Zinn, N., Sweetman, G. et al., Measuring and managing ratio compression for accurate iTRAQ/TMT quantification. J. Proteome Res. 2013, 12, 3586-3598.
24. Marksteiner, J., Bauer, R., Kaufmann, W. A., Weiss, E. et al., PE-11, a peptide derived from chromogranin B, in the human brain. Neuroscience 1999, 91, 1155-1170.
25. Fischer-Colbrie, R., Hagn, C. S. M., Chromogranins A, B, and C: widespread constituents of secretory vesicles. Ann. N. Y. Acad. Sci. 1987, 493, 120-134.
26. Eder, U., Leitner, B., Kirchmair, R., Pohl, P. et al., Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases. J. Neural Transm. 1998, 105, 39-51.
27. Guldbrandsen, A., Vethe, H., Farag, Y., Oveland, E. et al., In-depth characterization of the cerebrospinal fluid proteome displayed through the CSF Proteome Resource (CSF-PR). Mol. Cell. Proteomics 2014, 13, 3152-3163.
28. Canto, E., Tintore, M., Villar, L. M., Costa, C. et al., Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain 2015, 138, 918-931.
29. Schutzer, S., Angel, T., Liu, T., Schepmoes, A. et al., Gray matter is targeted in first-attack multiple sclerosis. PloS One 2013, 8: e66117.
30. Taupenot, L., Harper, K. L., O'Connor, D. T., Mechanisms of disease - the chromogranin-secretogranin family. N. Engl. J. Med. 2003, 348, 1134-1149.
31. Schmidt, S., Mo, M., Heidrich, F. M., Celic, A., Ehrlich, B. E., C-terminal domain of chromogranin B regulates intracellular calcium signaling. J. Biol. Chem. 2011, 286, 44888-44896.
32. Stys, P. K., Waxman, S. G., Ransom, B. R., Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na+ channels and Na(+)-Ca2+ exchanger. J. Neurosci. 1992, 12, 430-439.
33. Kornek, B., Storch, M. K., Bauer, J., Djamshidian, A. et al., Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 2001, 124, 1114-1124.
34. Craner, M. J., Newcombe, J., Black, J. A., Hartle, C. et al., Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 8168-8173.
35. Guyton, M. K., Wingrave, J. M., Yallapragada, A. V., Wilford, G. G. et al., Upregulation of calpain correlates with increased neurodegeneration in acute experimental auto-immune encephalomyelitis. J. Neurosci. Res. 2005, 81, 53-61.
36. Mo, M., Hoang, H. T., Schmidt, S., Clark, R. B., Ehrlich, B. E., The role of chromogranin B in an animal model of multiple sclerosis. Mol. Cell. Neurosci. 2013, 56, 102-114.